In Vitro susceptibilities of wild and drug resistant Leishmania donovani amastigotes to piperolactam A loaded hydroxypropyl-β-cyclodextrin nanoparticles

Acta Tropica

Volumn 158, Issue , 2016, Pages 97-106

  Bhattacharya, Plaban ^a,b   Mondal, Subhasish ^a   Basak, Souvik ^c   Das, Pradeep ^d   Saha, Achintya ^b   Bera, Tanmoy ^a  

^a JADAVPUR UNIVERSITY   (India)

^b UNIVERSITY OF CALCUTTA   (India)

^c Dr B C Roy College of Pharmacy and Allied Health Sciences   (India)

^d INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

Cylodextrin nanoparticles; Macrophage uptake; Piperolactam A; Wild type and drug resistant strains

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANTILEISHMANIAL AGENT; FLUORESCEIN ISOTHIOCYANATE; LACTAM DERIVATIVE; NANOPARTICLE; PAROMOMYCIN; PIPEROLACTAM A; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; ANTIPROTOZOAL AGENT; BETA CYCLODEXTRIN DERIVATIVE; INDOLE ALKALOID; PLANT EXTRACT;

DRUG RESISTANCE; LEISHMANIASIS; NANOPARTICLE; PARASITE; PROTOZOAN;

AMASTIGOTE; ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTILEISHMANIAL ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; COMPLEX FORMATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG PURIFICATION; DRUG SAFETY; FEMALE; IC50; IN VITRO STUDY; INFRARED SPECTROSCOPY; INTERNALIZATION; LEISHMANIA DONOVANI; MALE; MOLECULAR STABILITY; MOUSE; NANOFABRICATION; NONHUMAN; PARTICLE SIZE; PERITONEUM MACROPHAGE; PIPER BETLE; X RAY DIFFRACTION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; LEISHMANIASIS; PLANT ROOT;

LEISHMANIA DONOVANI; PIPER BETLE;

ANIMALS; ANTIPROTOZOAL AGENTS; BETA-CYCLODEXTRINS; DRUG RESISTANCE; INDOLE ALKALOIDS; LEISHMANIA DONOVANI; LEISHMANIASIS; MICE; MICE, INBRED BALB C; NANOPARTICLES; PIPER BETLE; PLANT EXTRACTS; PLANT ROOTS;

EID: 84959480718     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2016.02.017     Document Type: Article

References (62)

1. Ali I., Khan F.G., Suri K.A., Gupta B.D., Satti N.K., Dutt P., et al. In vitro antifungal activity of hydroxychavicol isolated from Piper betle L. Ann. Clin. Microbiol. Antimicrob. 2010, 9:7.
2. Alvar J., Velez I.D., Bern C., Herrero M., Desjeux P., Cano J., et al. WHO leishmaniasis control team: leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012, 7:e35671.
3. Baek J.S., Cho C.W. 2-Hydroxypropyl-β-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells. J. Pharm. Pharmacol. 2013, 65(1):72-78.
4. Bhattacharjee S., Bhattacharjee A., Majumder S., Majumdar S.B., Majumdar S. Glycyrrhizic acid suppresses Cox-2 mediated anti-inflammatory responses during Leishmania donovani infection. J. Antimicrob. Chemother. 2012, 67(8):1905-1914.
5. Bhattacharya P., Saha A. Evaluation of reversible contraceptive potential of Cordia dichotoma leaves extract. Rev. Bras. Farmacogn. 2013, 23(2):342-350.
6. Bhattacharya P., Ghosh M., Chatterjee A., Bangal S., Saha A. Development of a validated stability-indicating high-performance thin-layer chromatographic method for the quantification of levetiracetam. J. Planar Chromatogr. 2014, 27(2):132-139.
7. Biyani N., Singh A.K., Mandal S., Chawla B., Madhubala R. Differential expression of proteins in antimony-susceptible and resistant isolates of Leishmania donovani. Mol. Biochem. Parasitol. 2011, 179(2):91-99.
8. Carrizosa M.J., Koskinen W.C., Hermosin M.C. Interactions of acidic herbicides bentazon and dicamba with organoclays. Soil Sci. Soc. Am J. 2004, 68(6):1863-1866.
9. Chakraborty B., Biswas S., Mondal S., Bera T. Stage specific developmental changes in the mitochondrial and surface membrane associated redox system of Leishmania donovani promastigote and amastigote. Biochemistry (Moscow) 2010, 75(4):494-504.
10. Chappuis F., Sundar S., Hailu A., Ghalib H., Rijal S., Peeling R.W., et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. Nat. Rev. Microbiol. 2007, 5(11):873-882.
11. Chen S.T., Dou J., Temple R., Agarwal R., Wu K., Walker S. New therapies from old medicines. Nat. Biotechnol. 2008, 26:1077-1083.
12. Correa J.E., Rios C.H., Del R.C.A., Romero L.I., Ortega-Barria E., Coley P.D., et al. Minor alkaloids from Guatteria dumetorum with antileishmanial activity. Planta Med. 2006, 72(3):270-272.
13. Croft S.L., Sundar S., Fairlamb A.H. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 2006, 19(1):111-126.
14. Debrabant A., Joshi M.B., Pimenta P.F., Dwyer D.M. Generation of Leishmania donovani axenic amastigotes: their growth and biological characteristics. Int. J. Parasitol. 2004, 34(2):205-217.
15. Demicheli C., Ochoa R., Silva D.J.B., Falcao C.A., Rossi-Bergmann B., Melo D.A.L., et al. Oral delivery of meglumine antimonite-beta-cyclodextrin complex for treatment of leishmaniasis. Antimicrob. Agents Chemother. 2004, 48(1):100-103.
16. Desai S.J., Prabhu B.R., Mulchandani N.B. Aristolactams and 4,5-dioxoaporphines from Piper longum. Phytochemistry 1988, 27(5):1511-1515.
17. Dinan L., Harmatha J., Lafont R. Chromatographic procedures for the isolation of plant steroids. J. Chromatogr. A 2001, 935(1-2):105-123.
18. Faraut-Gambarelli F., Piarroux R., Deniau M., Giusiano B., Marty P., Michel G., et al. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob. Agents Chemother. 1997, 41(4):827-830.
19. Gradoni L., Soteriadou K., Louzir H., Dakkak A., Toz S.O., Jaffe C., et al. Drug regimens for visceral leishmaniasis in Mediterranean countries. Trop. Med. Int. Health 2008, 13(10):1272-1276.
20. Harborne J.B. Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis 1998, Springer, London.
21. 50 in studies of drug resistance of malaria parasites. Acta Trop. 1993, 55(4):257-261.
22. Iovannisci D.M., Ullman B. High efficiency plating method for Leishmania promastigotes in semi-defined or completely-defined media. J. Parasitol. 1983, 69(4):633-636.
23. Jackson J.E., Tally J.D., Ellis W.Y., Mebrahtu Y.B., Lawyer P.G., Were J.B., et al. Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania sp. from patients unresponsive to pentavalent antimony therapy. Am. J. Trop. Med. Hyg. 1990, 43(5):464-480.
24. Jhingran A., Chawla B., Saxena S., Barett M.P., Madhubala R. Paromomycin: uptake and resistance in Leishmania donovani. Mol. Biochem. Parasitol. 2009, 164(2):111-117.
25. Kar K., Mukherji K., Naskar K., Bhattacharya A., Ghosh D.K. Leishmania donovani: a chemically defined medium suitable for cultivation and cloning of promastigotes and transformation of amastigotes to promastigotes. J. Protozool. 1990, 37(4):277-279.
26. Lee S.L., Dou J., Agarwal R., Temple R., Beitz J., Wu C., et al. Evolution of traditional medicines to botanical drugs. Science 2015, 347:S32-S34.
27. Levrier C., Balastrier M., Beattie K.D., Carroll A.R., Martin F., Choomuenwai V., et al. Pyridocoumarin, aristolactam and aporphine alkaloids from the Australian rainforest plant Goniothalamus australis. Phytochemistry 2013, 86:121-126.
28. Lin C.F., Hwang T.L., Chien C.C., Tu H.Y., Lay H.L. A new hydroxychavicol dimer from the roots of Piper betle. Molecules 2013, 18(3):2563-2570.
29. Lira R., Sundar S., Makharia A., Kenney R., Gam A., Saraiya E., et al. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 1999, 180(2):564-567.
30. Lo W.L., Chang F.R., Wu Y.C. Alkaloids from the leaves of Fissistigma glaucescens. J. Chin. Chem Soc. 2000, 47(6):1251-1256.
31. Marques A.M., Velozo L.S., Moreira D.D.L., Guimaraes E.F., Kaplan M.A. Aristolactams from roots of Ottonia anisum (Piperaceae). Nat. Prod. Commun. 2011, 6(7):939-942.
32. Mattock N.M., Peters W. The experimental chemotherapy of leishmaniasis. II. The activity in tissue culture of some antiparasitic and antimicrobial compounds in clinical use. Ann. Trop. Med. Parasitol. 1975, 69(3):359-371.
33. Memisoglu E., Bochot A., Ozalp M., Sen M., Duchene D., Hincal A.A. Direct formation of nanospheres from amphiphilic beta-cyclodextrin inclusion complexes. Pharm. Res. 2003, 20(1):117-125.
34. Miguel D.C., Yokoyama-Yasunaka J.K., Andreoli W.K., Mortara R.A., Uliana S.R. Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorus vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. J. Antimicrob. Chemother. 2007, 60(3):526-534.
35. Misra P., Kumar A., Khare P., Gupta S., Kumar N., Dube A. Pro-apoptotic effect of the landrace Bangla Mahoba of Piper betle on Leishmania donovani may be due to the high content of eugenol. J. Med. Microbiol. 2009, 58(8):1058-1066.
36. Mondal S., Roy P., Das S., Halder A., Mukherjee A., Bera T. In Vitro susceptibilities of wild and drug resistant Leishmania donovani amastigote stages to andrographolide nanoparticle: role of vitamin E derivative TPGS for nanoparticle efficacy. PLoS One 2013, 8:e81492.
37. Mondal S., Roy J.J., Bera T. Characterization of mitochondrial bioenergetic functions between two forms of Leishmania donovani-a comparative analysis. J. Bioenerg. Biomembr. 2014, 46:395-402.
38. Mondal S., Roy J.J., Bera T. Generation of adenosine tri-phosphate in Leishmania donovani amastigote forms. Acta Parasitol. 2014, 59(1):11-16.
39. Montenegro H., Gutierrez M., Romero L.I., Ortega-Barria E., Capson T.L., Rios L.C. Aporphine alkaloids from Guatteria spp: with leishmanicidal activity. Planta Med. 2003, 69(7):677-679.
40. Mookerjee B.J., Mookerjee A., Banerjee R., Saha M., Singh S., Naskar K., et al. Inhibition of ABC transporters abolishes antimony resistance in Leishmania infection. Antimicrob. Agents Chemother. 2008, 52(3):1080-1093.
41. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012, 75(3):311-335.
42. Nwaka S., Hudson A. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov. 2006, 5(11):941-955.
43. Odalo J.O., Joseph C.C., Nkunya M.H., Sattler I., Lange C., Friedrich G., et al. Aristolactams, 1-(2-C-methyl-beta-d-ribofuranosyl)-uracil and other bioactive constituents of Toussaintia orientalis. Nat. Prod. Commun. 2010, 5(2):253-258.
44. Peine K.J., Gupta G., Brackman D.J., Papenfuss T.L., Ainslie K.M., Satoskar A.R., et al. et al. Liposomal resiquimod for the treatment of Leishmania donovani infection. J. Antimicrob Chemother. 2014, 69(1):168-175.
45. Perez-Victoria F.J., Castanys S., Gamarro F. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob. Agents Chemother. 2003, 47(8):2397-2403.
46. Peters W., Trotter E.R., Robinson B.L. The experimental chemotherapy of leishmaniasis, VII. Drug responses of L. major and L. mexicana amazonensis, with an analysis of promising chemical leads to new antileishmanial agents. Ann. Trop. Med. Parasitol. 1980, 74(3):321-335.
47. Pucadyil T.J., Tewary P., Madhubala R., Chattopadhyay A. Cholesterol is required for Leishmania donovani infection: implications in leishmaniasis. Mol. Biochem. Parasitol. 2004, 133(2):145-152.
48. Rasoanaivo P., Wright C.W., Willcox M.L., Gilbert B. Whole plant extracts versus single compounds for the treatment of malaria: synergy and positive interactions. Malar. J. 2011, 10(Suppl. 1):S4.
49. Reithinger R., Dujardin J.C., Louzir H., Pirmez C., Alexander B., Brooker S. Cutaneous leishmaniasis. Lancet Infect. Dis. 2007, 7(9):581-596.
50. Rojas R., Valderrama L., Valderrama M., Varona M.X., Ouellette M., Saravia N.G. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J. Infect. Dis. 2006, 193(10):1375-1383.
51. Roy P., Das S., Bera T., Mondol S., Mukherjee A. Andrographolide nanoparticles in leishmaniasis: characterization and in vitro evaluations. Int. J. Nanomed. 2010, 5:1113-1121.
52. Sarkar A., Sen R., Saha P., Ganguly S., Mandal G., Chatterjee M. An ethanolic extract of leaves of Piper betle (Paan) Linn mediates its antileishmanial activity via apoptosis. Parasitol. Res. 2008, 102(6):1249-1255.
53. Sasidharan S., Chen Y., Saravanan D., Sundram K.M., Yoga L.L. Extraction, isolation and characterization of bioactive compounds from plants extracts. Afr. J. Tradit. Complement. Altern. Med. 2011, 8(1):1-10.
54. Silva F.M.A.D., Koolen H.H.F., Lima J.P.S.D., Santos D.M.F., Jardim I.S., Souza A.D.L.D., et al. Leishmanicidal activities of fractions rich in aporphine alkaloids from Amazonian Unonopsis species. Rev. Bras. Farmacogn. 2012, 22(6):1368-1371.
55. Singh P.S., Kumar M. Current treatment of visceral leishmaniasis (Kala-azar): an overview. Int. J. Res. Med. Sci. 2014, 2(3):810-817.
56. Siqueira-Neto J.L., Song O., Oh H., Sohn J., Yang G., Nam J., et al. Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds. PLoS Negl. Trop. Dis. 2010, 4(5):e675.
57. Stella V.J., He Q. Cyclodextrins. Toxicol. Pathol. 2008, 36(1):30-42.
58. Sundar S., More D.K., Singh M.K., Singh V.P., Sharma S., Makharia A. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 2000, 31(4):1104-1107.
59. Teixeira M.C., Jesus D.S.R., Sampaio R.B., Pontes-de-Carvalho L., dos-Santos W.L. A simple and reproducible method to obtain large numbers of axenic amastigotes of different Leishmania species. Parasitol. Res. 2002, 88(11):963-968.
60. Thakur C.P., Pandey A.K., Sinha G.P., Roy S., Behbehani K., Olliaro P. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized Dose-finding study. Trans. R. Soc. Trop. Med. Hyg. 1996, 90(3):319-322.
61. Waechter A.I., Cave A., Hocquemiller R., Bories C., Munoz V., Fournet A. Antiprotozoal activities of aporphine alkaloids isolated from Unonopsis buchtienii (Annonaceae). Phytother. Res. 1999, 13(2):175-177.
62. Yang D.L., Mei W.L., Wang H., Dai H.F. Antimicrobial alkaloids from the tubers of Stephania succifera. Z. Naturforsch. Sect. B 2010, 65:757-761.